Holen Sie sich die Stockscreener-App
0.393
0.56%
-0.0022
Leap Therapeutics Inc Aktie (LPTX) Neueste Nachrichten
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Leap Therapeutics Reports Increased Q1 Losses - TipRanks
Metastatic Colorectal Cancer Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
2025 R&D layoffs and restructuring tracker - R&D World
HC Wainwright Issues Optimistic Outlook for LPTX Earnings - Defense World
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Cash-strapped Cambridge cancer biotech cuts 50% of its staff - NBC Boston
Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals
Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' - Fierce Biotech
Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com
Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus
Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune
Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com
Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq
LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times
Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX
LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com
75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World
Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus
Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PR Newswire
Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus
Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire
HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World
Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Leap reports progress in colorectal cancer study By Investing.com - Investing.com South Africa
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment - Financial Content
Micro Cap Soars Following Preliminary Data Update - The Globe and Mail
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Yahoo
LEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly Earnings - Nasdaq
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial - MarketScreener
Leap Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - MarketScreener
Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer - Nasdaq
Leap Therapeutics Reports Fourth Quarter And FY 2024 Results - Marketscreener.com
Leap reports progress in colorectal cancer study - Investing.com India
Breakthrough: Leap's Colorectal Cancer Drug Delivers 32% Higher Response Rate in Latest Trial - Stock Titan
Tobacco Control Has Saved Nearly 4 Millions Lives, Study Estimates - 69News WFMZ-TV
Leap Therapeutics stock hits 52-week low at $0.39 - Investing.com
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):